Vabysmo® Now Publicly Funded for Retinal Vein Occlusion and Pre-Filled Syringe in Quebec
Tuesday, August 19 2025 | 13 h 46 min | News
Hoffmann-La Roche Limited (Roche Canada) has announced that Vabysmo® (faricimab injection) is now publicly funded in Quebec for the treatment of macular edema secondary to retinal vein occlusion (RVO). The medication has been added to the Régie de l’assurance maladie du Québec (RAMQ) list of reimbursed drugs.
The update also includes coverage of Vabysmo in a 6.0 mg single-use pre-filled syringe (PFS) format, offering another treatment option for patients and prescribers. Health Canada authorized Vabysmo for RVO in July 2024, followed by approval of the PFS format in December 2024.
With this latest decision, Quebec now covers Vabysmo for all three of its approved indications: neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema secondary to RVO.
RVO, along with nAMD and DME, are among the leading causes of vision loss worldwide. According to international data, these conditions affect tens of millions of people and can have significant impact on patients’ quality of life, as well as on families and caregivers.
“This reimbursement for RVO in Quebec is a significant step forward for people living with the condition,” said Dr. Ananda Kalevar, Associate Professor in the Department of Ophthalmology at Sherbrooke University. “It provides ophthalmologists with an important treatment option and expands access for patients.”
Roche Canada indicated that it will continue working with other provincial drug plans to expand access to Vabysmo across the country.
Source: Roche Canada
Want to see more like this article? Click here to subscribe to our FREE print magazines and e-newsletters!
